共 50 条
- [31] Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Wu, Chiao-EnChen, Shin-ChehChang, Hsien-KunLo, Yung-FengHsueh, SweiLin, Yung-Chang
- [32] A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerCLINICAL CANCER RESEARCH, 2020, 26 (23) : 6149 - 6157Krop, IanAbramson, VandanaColleoni, MarcoTraina, TiffanyHolmes, FrankieGarcia-Estevez, LauraHart, LowellAwada, AhmadZamagni, ClaudioMorris, Patrick G.Schwartzberg, LeeChan, StephenGucalp, AycaBiganzoli, LauraSteinberg, JoyceSica, LorenzoTrudeau, MaureenMarkova, DenkaTarazi, JamalZhu, ZhouO'Brien, ThomasKelly, Catherine M.Winer, EricYardley, Denise A.
- [33] Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancerEJC SUPPLEMENTS, 2010, 8 (03): : 62 - 62Hasenburg, A.van de Velde, C. J. H.Seynaeve, C.Rea, D. W.Vannetzel, J.Paridaens, R.Markopoulos, C.Hozumi, Y.Putter, H.Jones, S. E.
- [34] Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II TrialACTA MEDICA OKAYAMA, 2015, 69 (05) : 291 - 299Sugiu, KumiIwamoto, TakayukiKelly, Catherine M.Watanabe, NaokiMotoki, TakayukiItoh, MitsuyaOhtani, ShoichiroHigaki, KenjiImada, TakakoYuasa, TakeshiOmori, MasakoSonobe, HiroshiFujiwara, ToshiyoshiMatsuoka, Junji
- [35] A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years - Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)CANCER RESEARCH, 2019, 79 (04)Ohtani, S.Iijima, K.Higaki, K.Sato, Y.Hozumi, Y.Hasegawa, Y.Takei, H.Tanaka, M.Yagata, H.Masuoka, H.Tanabe, M.Egawa, C.Komoike, Y.Saji, S.Nakamura, T.Yanagita, Y.Ohtsu, H.Mukai, H.Iwase, T.
- [36] A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222CLINICAL CANCER RESEARCH, 2022, 28 (04) : 611 - 617Moore, Halle C. F.Barlow, William E.Somlo, GeorgeGralow, Julie R.Schott, Anne F.Hayes, Daniel F.Kuhn, PeterHicks, James B.Welter, LisaDy, Philip A.Yeon, Christina H.Conlin, Alison K.Balcueva, ErnieLew, Danika L.Tripathy, DebasishPusztai, LajosHortobagyi, Gabriel N.
- [37] First-line bevacizumab (BEV) plus chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.CANCER RESEARCH, 2013, 73 (08)Kahan, ZsuzsannaPetruzelka, LubosEniu, AlexandruAnghel, RodicaKoynov, KrassimirVrbanec, DamirLang, IstvanAhlers, SilkeBrodowicz, ThomasZielinski, Christoph
- [38] E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Connolly, Roisin M.Zhao, FengminMiller, KathyTevaarwerk, AmyeWagner, Lynne I.Lee, Min-JungMurray, JudyGray, Robert JamesPiekarz, RichardZujewski, Jo AnneSparano, Joseph A.
- [39] Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial (vol 22, pg 74, 2021)LANCET ONCOLOGY, 2022, 23 (10): : E446 - E446Saad, F.Thiery-Vuillemin, A.Wiechno, P.